ArticlePloS one2026
Antimicrobial and anti-biofilm activities of Vernonia amygdalina and Senna siamea leaf extracts against pathogenic bacteria.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The study assessed the antibacterial and antibiofilm capability of Vernonia amygdalina and Senna siamea against both ESBL- and non-ESBL-producing bacteria. The result from the phytochemical screening revealed that secondary metabolites such as alkaloids, flavonoids, saponins, tannins, coumarins, triterpenoids, and phytosteroids were present in both plants, except glycosides, which were exclusively detected in Vernonia amygdalina. The antibacterial activity showed that Senna siamea had its highest zone of inhibition against K. pneumoniae, whereas Vernonia amygdalina recorded its highest effect on E. coli. The MIC values for Senna siamea ranged from 6.25 to 25.00 mg/mL, while the MICs of Vernonia amygdalina ranged from 12.50 ± 0.00 to 50.00 ± 0.00 mg/mL. Combination testing indicated synergy between the two extracts only for E. coli. Antibiofilm assays showed clear dose-dependent inhibition. At 100 mg/mL, Vernonia amygdalina showed 99.01% inhibition against ESBL K. pneumoniae, while Senna siamea at the same concentration reached 99.72% against S. aureus. These data demonstrate the relevant antibacterial and antibiofilm activities for each extract and support continuing efforts that could include them in new strategies against resistant pathogens, including ESBL-producers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.